Cartesian Therapeutics(RNAC)
$6.88-0.01 (-0.15%)
RNAC
Cartesian Therapeutics financials statements
$6.88
At close:-0.01 (-0.15%)
Want to see RNAC full AI Analyst Report?
Cartesian Therapeutics (RNAC) Ratios
1,213 Followers
Cartesian Therapeutics Ratios
RNAC's free cash flow for Q3 2026 was $-28.17M. For the 2026 fiscal year, RNAC's free cash flow was decreased by $-441.00K and operating cash flow was $-27.73M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.65 | 9.43 | 1.33 | 5.91 | 2.00 |
| Quick Ratio | 8.65 | 9.43 | 1.33 | 5.91 | 2.00 |
| Cash Ratio | 8.38 | 9.25 | 1.13 | 4.24 | 1.58 |
| Solvency Ratio | -0.30 | -0.17 | -0.29 | 0.52 | -0.17 |
| Operating Cash Flow Ratio | -4.95 | -1.03 | -0.75 | -1.26 | -0.84 |
| Short-Term Operating Cash Flow Coverage | -17.81 | 0.00 | 0.00 | -3.73 | -10.13 |
| Net Current Asset Value | $ -293.38M | $ -225.20M | $ -654.50M | $ 76.08M | $ 7.08M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.03 | 0.04 | 0.23 | 0.22 |
| Debt-to-Equity Ratio | -0.10 | -2.06 | -0.02 | 0.40 | 1.57 |
| Debt-to-Capital Ratio | -0.11 | 1.95 | -0.03 | 0.29 | 0.61 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.16 | 0.47 |
| Financial Leverage Ratio | -2.35 | -63.96 | -0.69 | 1.77 | 7.10 |
| Debt Service Coverage Ratio | -30.68 | 0.00 | -76.26 | 3.51 | -2.40 |
| Interest Coverage Ratio | 0.00 | 0.00 | -30.50 | 4.80 | -1.62 |
| Debt to Market Cap | 0.02 | 0.00 | 0.00 | 0.19 | 0.08 |
| Interest Debt Per Share | 0.49 | 0.54 | 2.67 | 10.19 | 12.00 |
| Net Debt to EBITDA | 0.82 | 2.61 | 0.28 | -1.72 | 15.27 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 98.16% | 100.00% |
| EBIT Margin | -4987.31% | -198.23% | -907.08% | 34.12% | -8.08% |
| EBITDA Margin | -4881.52% | -195.27% | -903.84% | 35.96% | -6.06% |
| Operating Profit Margin | -3099.93% | -112.81% | -332.32% | 13.12% | -5.40% |
| Pretax Profit Margin | -4987.31% | -198.23% | -917.97% | 31.39% | -11.43% |
| Net Profit Margin | -4658.63% | -198.97% | -844.91% | 31.94% | -30.19% |
| Continuous Operations Profit Margin | -4658.63% | -198.97% | -844.91% | 31.94% | -30.19% |
| Net Income Per EBT | 93.41% | 100.37% | 92.04% | 101.75% | 264.24% |
| EBT Per EBIT | 160.88% | 175.72% | 276.23% | 239.17% | 211.46% |
| Return on Assets (ROA) | -43.96% | -17.80% | -72.02% | 21.33% | -16.07% |
| Return on Equity (ROE) | 103.22% | 1138.25% | 49.91% | 37.71% | -114.06% |
| Return on Capital Employed (ROCE) | -30.80% | -10.65% | -36.49% | 10.32% | -5.25% |
| Return on Invested Capital (ROIC) | -28.36% | -10.58% | -33.28% | 9.63% | -4.86% |
| Return on Tangible Assets | -52.49% | -32.77% | -206.71% | 21.33% | -16.07% |
| Earnings Yield | -69.58% | -16.69% | -216.15% | 25.95% | -8.27% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.51 | 44.63 | 2.94 | 11.24 | 8.58 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 6.45 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.16 | 2.52 | 2.13 | 7.69 | 7.11 |
| Asset Turnover | 0.01 | 0.09 | 0.09 | 0.67 | 0.53 |
| Working Capital Turnover Ratio | 0.02 | 0.36 | 0.36 | 1.13 | 1.20 |
| Cash Conversion Cycle | 145.50 | 8.18 | 124.24 | -24.14 | 42.53 |
| Days of Sales Outstanding | 145.50 | 8.18 | 124.24 | 32.48 | 42.53 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 56.62 | 0.00 |
| Operating Cycle | 145.50 | 8.18 | 124.24 | 32.48 | 42.53 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.85 | -0.91 | -9.90 | -7.87 | -19.01 |
| Free Cash Flow Per Share | -3.06 | -1.26 | -9.93 | -8.16 | -19.35 |
| Dividend Paid and CapEx Coverage Ratio | -13.56 | -2.60 | -248.35 | -26.34 | -55.65 |
| Capital Expenditure Coverage Ratio | -13.56 | -2.60 | -248.35 | -26.34 | -55.65 |
| Operating Cash Flow Coverage Ratio | -5.83 | -1.69 | -4.67 | -0.83 | -1.71 |
| Operating Cash Flow to Sales Ratio | -26.44 | -0.61 | -1.97 | -0.29 | -0.71 |
| Free Cash Flow Yield | -42.40% | -7.06% | -50.53% | -24.09% | -19.79% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.44 | -5.99 | -0.46 | 3.85 | -12.09 |
| Price-to-Sales (P/S) Ratio | 66.95 | 11.92 | 3.91 | 1.23 | 3.65 |
| Price-to-Book (P/B) Ratio | -1.48 | -68.21 | -0.23 | 1.45 | 13.79 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.36 | -14.16 | -1.98 | -4.15 | -5.05 |
| Price-to-Operating Cash Flow Ratio | -2.53 | -19.60 | -1.99 | -4.31 | -5.14 |
| Price-to-Earnings Growth (PEG) Ratio | -0.03 | 0.06 | 0.00 | -0.02 | 0.18 |
| Enterprise Value Multiple | -0.55 | -3.49 | -0.15 | 1.70 | -44.94 |
| Enterprise Value | 74.80M | 265.33M | 35.69M | 67.80M | 231.82M |
| EV to EBITDA | -0.55 | -3.49 | -0.15 | 1.70 | -44.94 |
| EV to Sales | 26.74 | 6.82 | 1.37 | 0.61 | 2.72 |
| EV to Free Cash Flow | -0.94 | -8.10 | -0.69 | -2.07 | -3.77 |
| EV to Operating Cash Flow | -1.01 | -11.21 | -0.70 | -2.14 | -3.84 |
| Tangible Book Value Per Share | -6.71 | -7.94 | -123.58 | 23.33 | 7.09 |
| Shareholders’ Equity Per Share | -4.86 | -0.26 | -85.14 | 23.33 | 7.09 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.07 | -0.00 | 0.08 | -0.02 | -1.64 |
| Revenue Per Share | 0.11 | 1.50 | 5.03 | 27.55 | 26.79 |
| Net Income Per Share | -5.02 | -2.99 | -42.49 | 8.80 | -8.09 |
| Tax Burden | 0.93 | 1.00 | 0.92 | 1.02 | 2.64 |
| Interest Burden | 1.00 | 1.00 | 1.01 | 0.92 | 1.41 |
| Research & Development to Revenue | 20.75 | 1.16 | 2.74 | 0.65 | 0.81 |
| SG&A to Revenue | 11.25 | 0.77 | 1.56 | 0.22 | 0.25 |
| Stock-Based Compensation to Revenue | 3.76 | 0.17 | 0.87 | 0.10 | 0.09 |
| Income Quality | 0.57 | 0.31 | 0.23 | -0.89 | 2.35 |
Currency in USD
